SMS Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kvwfyi54x1fqvwawgvcscqdc.pdf

Key Takeaways


Performance & Margin Drivers

Potluri: "Backward integration gives us a structural cost advantage, not a temporary pricing benefit. And this quarter shows that clearly. It reflects 5 years of investments in backward integration and capacity building."

Ibuprofen: Capacity, Stability & Dependency

Potluri: "More important than the margins, the stability on the product... if we were not backward integrated, we would have been caught napping and we wouldn't have -- we wouldn't actually have the product to -- the intermediate to actually manufacture ibuprofen."

Peptides: Early-Stage Build-Out

Potluri: "It might take a little while for us to attract the real top names in the industry to come and work on CRO and CDMO with us. But definitely, I think in the next 2 to 3 years, we anticipate a meaningful revenue coming out from the peptides."

Capex, New Molecules & Balance Sheet


Segment & Partnership Dynamics

SegmentH1 FY27 TrendCommentary
ARVs▲ Strong growthGrew 47% YoY to ₹150 crores on market share gains.
Anti-inflammatory▲ Solid growthGrew 25% YoY to ₹110 crores, driven by ibuprofen demand from regulated markets.
High-value APIs▲ Mix improvingShare climbed to 49% of H1 revenue from 47% in FY26, with structural advantage from scale and backward integration.
Chemo partnership▬ SteadyNearly 10-year partnership ongoing; products like sitagliptins and flozins developed under a JV with profit share.

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue and marginExceed original guidance of 15% revenue growth and 20% EBITDA marginFY27 full year
Ibuprofen capacityReach 9,600 tons per year total capacityComing quarters
Ibuprofen full utilizationAchieve 90% occupancy of 9,600-ton capacity6–8 months after capacity completion
Capex program completionDeploy remaining ~₹120 cr of ₹280 cr programBy end of FY27
New molecule commercial production6–8 new molecules begin commercial productionFY28
Peptides pilot scalePilot-level peptide samples producedQ4 FY27
Peptides first CRO revenueFirst CRO revenue from peptides subsidiaryQ2 FY28
Peptides meaningful revenueMeaningful revenue contribution from peptidesNext 2–3 years
Ibuprofen dependency capKeep ibuprofen below 35% of total revenueOngoing
Working capital cycleMaintain 120–150 day cycleGoing forward
FY28 EBITDA marginAchieve 22%–24% EBITDA marginFY28

Key Metrics

MetricQ2 FY27
Revenue from operations₹316 cr, +30% YoY and +53% QoQ
Gross profit₹111 cr, +41% YoY
Gross margin35%, vs 32% in Q2 FY26 and 36% in Q1 FY27
EBITDA₹68 cr, +40% YoY
EBITDA margin21%, expanded 145 bps YoY
PAT₹39.6 cr, +57% YoY
PAT margin~13%
H1 FY27 revenue₹523 cr, +19% YoY
H1 FY27 EBITDA margin21%
H1 FY27 PAT₹59.8 cr, +36% YoY; including VKT profit share: ₹60.8 cr, +33% YoY
FY27 revenue growth guidanceExceeding 15%, original guidance was 15%
FY27 EBITDA margin guidanceExceeding 20%, original guidance was 20%
FY28 EBITDA margin target22% to 24%
High-value APIs share of revenue49% in H1 FY27, up from 47% in FY26
Ibuprofen capacity utilization90% to 95% of existing capacity
Ibuprofen monthly production450 to 500 tons
Ibuprofen total capacity target9,600 tons per year, capex to complete in coming quarters
Capex deployed₹160 cr of ₹280 cr program, on track for completion by FY27
Peak debt expected by end of FY27~₹400 cr, long-term and short-term combined
Working capital cycle120 to 150 days
H1 FY27 cash flow conversion ratio~93% to 95%
Fixed asset turnover (excl. capital WIP)1.72x
R&D filings in FY276 filings so far (4 in H1, 2 in October), FY27 target of 10
New molecules for commercial production in FY286 to 8
Peptides R&D team~30 chemists, mostly PhDs
Loan approved for SMS Peptides subsidiary₹50 cr